CureVac AG : Founding Co of mRNA space (last round $1bn+). Naturally sequenced, optimized mRNA. Intratumoral therapy Ph1 (multiple onc indications) initiated Q4 17, early data rep at SITC. First pt enrolled Ph 1 prophylactic mRNA rabies vax Oct 2018. Prophylactic influenza vax initiation Ph 1 2020, OTC deficiency Ph 1 initiation H219. Interim data /all trials: 2019. Collabs w B. Ingelheim, Sanofi, Gates, IAVI, LLY, CRISPr Tx.
Sector/industry:
Biotech Company
Characteristics:
Based in...
Europe
Clinical Stage
Phase l or ll
Disease Space
Anti-infectives, Antivirals, Autoimmune, Oncology
Finance
Pre-Revenues
Industry
Biotechnology
Listing
Private
Therapeutic Modalities
Platform Technology
Website:
Address:
Paul-Ehrlich-Straße 15
Tübingen, 72076
Germany

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.